Dewpoint Therapeutics Inc., a biotechnology company developing condensate-modulating medicines, has selected a development candidate for its MYC oncology programme, marking a key step toward advancing a first-in-class small molecule designed to regulate MYC-driven cancer biology.

MYC is a central regulator of oncogenic transcription linked to multiple high-burden cancers, but it has historically proven difficult to target with conventional drug discovery strategies. Dewpoint’s candidate is engineered to disrupt MYC-dependent transcription by modulating abnormal biomolecular condensates — dynamic cellular structures that organise transcriptional machinery in tumour cells.

The company selected the candidate following a comprehensive preclinical evaluation demonstrating strong potency and selectivity in MYC-dependent cellular systems, favourable in vivo pharmacology, tumour regression signals in MYC-driven models, and a tolerability profile supportive of progression into IND-enabling studies. Dewpoint intends to explore the therapy across tumour settings where MYC signalling is a primary oncogenic driver.

According to the company, the molecule represents the first MYC-focused condensate-modulating small molecule to reach development candidate status. By targeting condensate-level transcription organisation, the approach introduces a mechanistically distinct strategy that may enable improved selectivity and therapeutic control in MYC-driven cancers.

Dewpoint plans to advance the programme through formal IND-enabling development while continuing research into MYC condensate biology across cancer models to refine translational applications.

Biomolecular condensates are membraneless cellular compartments formed through phase separation that help organise biochemical activity inside cells. Their dysregulation has been linked to a wide spectrum of diseases, including cancer and metabolic and neurological disorders. Condensate-modulating therapeutics are emerging as a new drug class aimed at addressing complex biological pathways and historically difficult targets.